The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature

• Publication date

  2014-02-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature12998PMID 24553136PMCID PMC6258903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Roadblocks to translational advances on metastasis research

  2013cited by this paper
• The role of ubiquitylation in receptor endocytosis and endosomal sorting

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Essential Role of E3 Ubiquitin Ligase Activity in Cbl-b–Regulated T Cell Functions

  2011cited by this paper
• Differential Effects of EGFR Ligands on Endocytic Sorting of the Receptor

  2009cited by this paper
• Mechanisms of NKT cell anergy induction involve Cbl-b-promoted monoubiquitination of CARMA1

  2009cited by this paper
• Immunotherapy of autoimmunity and cancer: the penalty for success

  2008cited by this paper
• The Cbl-b RING finger domain has a limited role in regulating inflammatory cytokine production by IgE-activated mast cells.

  2008cited by this paper
• Immunobiology of the TAM receptors

  2008cited by this paper
• TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

  2008cited by this paper
• Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46

  2007cited by this paper
• Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells

  2007cited by this paper
• Ablation of Cbl-b provides protection against transplanted and spontaneous tumors.

  2007cited by this paper
• Molecular and Genetic Basis for Strain-Dependent NK1.1 Alloreactivity of Mouse NK Cells

  2006cited by this paper
• Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases

  2006cited by this paper
• Molecular and Genetic Basis for Strain-Dependent NK1.1 Alloreactivity of Mouse NK Cells1

  2006cited by this paper
• Warfarin: almost 60 years old and still causing problems.

  2006cited by this paper
• Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation.

  2005cited by this paper
• The role of γ‐carboxylation in the anti‐apoptotic function of gas6

  2005cited by this paper
• Proteome-wide Identification of Cellular Targets Affected by Bisindolylmaleimide-type Protein Kinase C Inhibitors*

  2004cited by this paper
• Immunobiology of Her-2/Neu Transgenic Mice

  2004cited by this paper
• An efficient proteomics method to identify the cellular targets of protein kinase inhibitors

  2003cited by this paper
• Growth Arrest-specific Gene 6 Is Involved in Glomerular Hypertrophy in the Early Stage of Diabetic Nephropathy*

  2003cited by this paper
• The role of the NKG2D immunoreceptor in immune cell activation and natural killing.

  2002cited by this paper
• Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis.

  2001cited by this paper
• Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family

  2001cited by this paper
• Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo

  2001cited by this paper
• Development of a novel flow cytometric cell-mediated cytotoxicity assay using the fluorophores PKH-26 and TO-PRO-3 iodide.

  2001cited by this paper
• Mouse 4T1 Breast Tumor Model

  2000cited by this paper
• Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b

  2000cited by this paper
• Identification of the Product of Growth Arrest-specific Gene 6 as a Common Ligand for Axl, Sky, and Mer Receptor Tyrosine Kinases*

  1996cited by this paper
• Predominant expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations.

  1995cited by this paper
• Predominant expression of invariant Vα14+ TCR α chain in NK1.1+ T cell populations

  1995cited by this paper
• In vivo depletion of natural killer cell activity leads to enhanced multiplication of Mycobacterium avium complex in mice

  1991cited by this paper
• Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth.

  1989cited by this paper
• In vivo effect of anti-asialo GM1 antibody on natural killer activity

  1981cited by this paper
• A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases.

  1973cited by this paper
• Reduced Incidence of Spontaneous Metastases with Long‐Term Coumadin* Therapy

  1968cited by this paper
• [Effect of dicoumarol on the development of metastases of the T8 epithelioma in the rat; new research].

  1957cited by this paper

• Resident CD49a+CD103+NKG2C+ NK cells restrict HIV infection in human lymphoid tissue explants

  2026cites this paper
• Navigating TAM receptor dynamics in tumour immunotherapy

  2025cites this paper
• Comparing survival with vitamin K antagonists, low-molecular-weight heparin, and direct oral anticoagulants in patients with cancer—a systematic review and meta-analysis

  2025cites this paper
• Immune Microenvironment in Breast Cancer Metastasis.

  2025cites this paper
• Calumenin, A Calcium‐Binding Modulatory Protein, Effective in Pathological Calcifications and Cancers, With Therapeutic Application Promise

  2025cites this paper
• Dual inhibition of AXL and MER kinase: scope for lung and breast cancer therapeutics.

  2025cites this paper
• Repurposing of the Syk inhibitor fostamatinib using a machine learning algorithm

  2025cites this paper
• Sitravatinib targets TYRO3 to augment the anti-tumor immune response of PD-1 blockade in hepatocellular carcinoma.

  2025cites this paper
• Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis

  2025cites this paper
• AXL: shapers of tumor progression and immunosuppressive microenvironments

  2025cites this paper
• Rescuing natural killer cells from the cancer wilderness

  2025cites this paper
• From pathogenesis to therapeutic targeting: new insight into TAM receptors in rheumatoid arthritis

  2025cites this paper
• Clinical Characteristics, Prognostic Factors and Therapeutic Strategies in Gastric Cancer Patients With Bone Metastasis: A Retrospective Analysis

  2025cites this paper
• Prospects of current AXL-targeting therapies in early phase cancer trials

  2025cites this paper
• Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.

  2025cites this paper
• Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial

  2025cites this paper
• Expression pattern and clinical significance of MerTK on circulating NK cells in systemic lupus erythematosus

  2025cites this paper
• Correction to: Accelerated vascular ageing after COVID-19 infection: the CARTESIAN study

  2025cites this paper
• Contribution of tumor microenvironment (TME) to tumor apoptosis, angiogenesis, metastasis, and drug resistance

  2025cites this paper
• Enhancing natural killer cell anti-tumour activity through macrophage manipulation

  2025cites this paper
• Vitamin K-dependent carboxylation in osteoblasts regulates bone resorption through GAS6 in male mice

  2025cites this paper
• At the intersection of immunology and oncology: TAM receptors in the regulation of immune responses and tumorigenesis-related processes

  2025cites this paper
• AXL in cardiovascular diseases: Pathophysiological insights and clinical perspectives.

  2025cites this paper
• Discovery of Phosphorylated Peptidomimetics Targeting Cbl-b SH2 Domain as Orthosteric Cbl-b Inhibitors by an Optimized Fluorescence Polarization Competition Assay.

  2025cites this paper
• The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice.

  2025cites this paper
• Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategies

  2025cites this paper
• Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation

  2025cites this paper
• Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL

  2025cites this paper
• Warfarin and bevacizumab suppress tumor progression in pancreatic ductal adenocarcinoma by targeting EGFR-PI3K-Akt signaling: inhibition of proliferation/migration and apoptosis induction

  2025cites this paper
• Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?

  2025influential citation
• NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways

  2025cites this paper
• The Sensitive Genes for Cervical Cancer: Two-Sample Mendelian Randomization with Experimental Validation

  2025cites this paper
• Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment

  2025cites this paper
• AXL Tyrosine Kinases: A Growing Isoform Family that Promotes Cancer Pathogenesis.

  2025cites this paper
• Transferrin Disassociates TCR from CD3 Signaling Apparatus to Promote Metastasis

  2024cites this paper
• Metastasis Models: Thermodynamics and Complexity.

  2024cites this paper
• AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer.

  2024cites this paper
• Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.

  2024cites this paper
• GAS6/TAM Axis as Therapeutic Target in Liver Diseases

  2024cites this paper
• Targeting Deltex E3 Ubiquitin Ligase 2 Inhibits Tumor‐associated Neutrophils and Sensitizes Hepatocellular Carcinoma Cells to Immunotherapy

  2024cites this paper
• TAM-preferential nanoparticles intracellularly self-assembled for enhanced macrophage repolarization and cancer immunotherapy

  2024cites this paper
• Mechanisms of Cbl-Mediated Ubiquitination of Proteins in T and Natural Killer Cells and Effects on Immune Cell Functions

  2024cites this paper
• AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

  2024cites this paper
• A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy

  2024cites this paper
• Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

  2024cites this paper
• MERTK inhibition selectively activates a DC – T-cell axis to provide anti-leukemia immunity

  2024cites this paper
• Intracellular checkpoints for NK cell cancer immunotherapy

  2024cites this paper
• Association between warfarin and survival in invasive melanoma: a population-based cohort study

  2024cites this paper
• Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets

  2024cites this paper
• Inhibition of Cbl-b restores effector functions of human intratumoral NK cells

  2024cites this paper
• A vascularized breast cancer spheroid platform for the ranked evaluation of tumor microenvironment-targeted drugs by light sheet fluorescence microscopy

  2024cites this paper
• Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy.

  2024cites this paper
• Advancements in clinical RNA therapeutics: Present developments and prospective outlooks

  2024cites this paper
• ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation

  2024cites this paper
• Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma

  2024cites this paper
• Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition

  2024cites this paper
• The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer

  2024cites this paper
• EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

  2024cites this paper
• Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b).

  2024cites this paper
• E3 ubiquitin ligase CBLB regulates innate immune responses and bacterial dissemination during nontuberculous mycobacteria infection.

  2024cites this paper
• Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate

  2024cites this paper
• MERTK Inhibition as a Targeted Novel Cancer Therapy

  2024cites this paper
• Roles of post-translational modifications of C-type lectin receptor-induced signaling cascades in innate immune responses against Candida albicans

  2023cites this paper
• TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells

  2023cites this paper
• AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming.

  2023cites this paper
• Breaching the Fortress of Tumor Microenvironment to Control Cancer Metastasis

  2023cites this paper
• Cancer metastasis: Molecular mechanisms and clinical perspectives.

  2023cites this paper
• NK cell-based tumor immunotherapy

  2023cites this paper
• Decreased epidermal AXL expression and increased infiltration of AXL‐expressing dendritic cells in psoriasis

  2023cites this paper
• Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors

  2023cites this paper
• Virtual screening indicates potential inhibitors of the P2X7 receptor

  2023cites this paper
• Renal cell carcinoma escapes NK cell‐mediated immune surveillance through the downregulation of DNAM‐1

  2023cites this paper
• AXL in cancer: a modulator of drug resistance and therapeutic target

  2023cites this paper
• AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells.

  2023cites this paper
• TAM family kinases as therapeutic targets at the interface of cancer and immunity

  2023influential citation
• UBR5 Significantly Correlates with Osteosarcomas Prognosis and Immune Exhaustion Characteristic in the Tumor Microenvironment.

  2023cites this paper
• 生物材料增效NK细胞免疫疗法研究进展

  2023influential citation
• Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies

  2023cites this paper
• Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets

  2023cites this paper
• The Elongin BC complex negatively regulates AXL and marks a differentiated phenotype in melanoma.

  2023cites this paper
• The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

  2023cites this paper
• Targeting Cbl-b in cancer immunotherapy

  2023cites this paper
• Chicken-derived MERTK protein inhibits Newcastle disease virus replication by increasing STAT1 phosphorylation in DF-1 cells

  2023cites this paper
• TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment

  2023cites this paper
• Vitamin K: a Potential Neuroprotective Agent

  2023cites this paper
• PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma

  2023cites this paper
• Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma

  2023cites this paper
• Therapeutic Landscape of AXL Receptor Kinase in Triple Negative Breast Cancer.

  2023cites this paper
• Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

  2023cites this paper
• Enzyme Inhibitors from Gorgonians and Soft Corals

  2023cites this paper
• Natural Killer Cell-Based Immunotherapy against Glioblastoma

  2023cites this paper
• The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy

  2023cites this paper
• Medical Countermeasure Requirements to Meet NASA’s Space Radiation Permissible Exposure Limits for a Mars Mission Scenario

  2022cites this paper
• Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy

  2022cites this paper
• Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review)

  2022cites this paper
• Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition

  2022cites this paper
• Upregulated flotillins and sphingosine kinase 2 derail AXL vesicular traffic to promote epithelial-mesenchymal transition.

  2022cites this paper
• The Entanglement between Mitochondrial DNA and Tumor Metastasis

  2022cites this paper
• MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

  2022cites this paper
• Targeting Cblb-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cells responses

  2022cites this paper